Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.51 |
| ▸ | BCL2 | P10415 | 1/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475231 | 0.87 | NPC1 (0.56) | LMNAMAPTL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL7040136 | 0.86 | CES2 (0.58) | LMNAMAPTL3MBTL1SRD5A2RAB9A | |
| SCHEMBL10351730 | 0.84 | MAPT (0.58) | LMNAMAPTL3MBTL1SRD5A2RAB9A | |
| SCHEMBL9240920 | 0.80 | HNF4A (0.58) | MAPTL3MBTL1SRD5A2RAB9AKDM4E | |
| SCHEMBL6204532 | 0.80 | TAS1R3 (0.56) | LMNAMAPTL3MBTL1SRD5A2RAB9A | |
| SCHEMBL6060544 | 0.80 | HTT (0.61) | MAPTRAB9AKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL10705887 | 0.79 | AKR1B1 (0.55) | LMNAMAPTL3MBTL1SRD5A2RAB9A | |
| SCHEMBL15197228 | 0.79 | GRM1 (0.60) | LMNAMAPTL3MBTL1SRD5A2RAB9A | |
| SCHEMBL7129800 | 0.78 | MAPT (0.80) | MAPTL3MBTL1SRD5A2RAB9AKDM4E | |
| SCHEMBL1515693 | 0.77 | L3MBTL1 (0.68) | LMNAMAPTL3MBTL1SRD5A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864309-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | Cadila Healthcare Limited (IN) | 2015-04-29 | — | — | EP | disclosed |
| US-20150051144-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | CADILA HEALTHCARE LTD (IN) | 2015-02-19 | — | — | US | disclosed |
| WO-2014002105-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2014-01-03 | — | — | WO | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051144-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | PCSK9, HMGCR, CETP | LMNA 277/4885MAPT 121/4885L3MBTL1 2707/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | LMNA 702/4885MAPT 3422/4885L3MBTL1 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.